Geron Corporation Reports 2005 First Quarter Financial Results and Events.

MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three months ended March 31, 2005.

For the first quarter of 2005, the company reported operating revenue of $59,000 and operating expenses of $10.4 million compared to $248,000 and $52.3 million, respectively, for the comparable period in 2004. Net loss for the period was $9.7 million or $(0.18) per share compared to $51.7 million or $(1.28) per share for the comparable period in 2004.

Operating expenses for the first quarter of 2004 included a non-cash charge of $45.2 million related to the acquisition of technology rights from Merix Bioscience, Inc. (now Argos Therapeutics). Excluding that charge, the company's overall research and development expenses increased in the first quarter of 2005 as a result of higher personnel-related costs and increased consulting costs for clinical and regulatory matters. The increase in the company's general and administrative expenses for 2005 was primarily due to a non-cash charge for the fair value of a warrant issued to a consultant.

The company expects its research and development expenses to increase in the future as it continues clinical manufacturing and testing of its telomerase inhibitor compounds, furthers the development of its human embryonic stem cell programs and expands its activities in the development of telomerase-based cancer vaccines.

Revenues for the first quarter of 2005 and 2004 represented royalty revenues under various license agreements with companies for sales of telomerase-based diagnostic kits, shared profits from sales of reagent research products, and license fee revenues recognized from sublicense agreements or license option agreements with various companies for nuclear transfer and telomerase technology.

First Quarter 2005 Highlights:

--The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office issued a final judgment ending patent interference number 104,746 between Geron and Advanced Cell Technology Corporation (ACT) of Worcester, Mass., having to do with claims related to nuclear transfer technology. The Board ended the interference by entering judgment against ACT on all counts in the priority phase of the interference, thereby invalidating U.S. Patent No. 5,945,577, which is licensed to ACT from the University of Massachusetts.

--Geron Corporation granted a worldwide license to Cambrex (NYSE:CBM) under which a Cambrex subsidiary will develop and distribute cell lines that have been immortalized using Geron's proprietary telomerase technology.

--Geron received proceeds of $12.5 million upon the exercise of warrants to purchase approximately 2.0 million shares of common stock. The warrants were issued to institutional investors in connection with the financing announced in November 2004 and had an expiration date of January 11, 2005.

--The Board of Patent Appeals and Interferences of the U.S. Patent and Trademark Office issued a final judgment in interference number 105,192 between Geron and ACT, having to do with claims related to nuclear transfer technology. In its ruling, the Board found all claims of U.S. Patent No. 6,235,970, which is licensed to ACT from the University of Massachusetts, to be unpatentable, effectively invalidating the patent.

--Geron and the Biotechnology Research Corporation (BRC) of Hong Kong formed a new company, TA Therapeutics, Limited (TAT), in Hong Kong. TAT will conduct research and develop telomerase activator drugs to restore the functional capacity of cells in various organ systems that have been impacted by senescence, injury or chronic disease.

--The Journal of Immunology published results of a completed Phase 1-2 clinical trial of Geron's telomerase therapeutic vaccine administered to patients with metastatic prostate cancer at Duke University Medical Center. The results showed that the vaccination protocol successfully generated telomerase-specific T-cell responses in 19 of 20 subjects. The vaccine was well tolerated with no major treatment-related toxicities.

--Geron's collaborators presented studies showing that small molecule telomerase activators, GRN139951 and GRN140665, enhanced the functional activity of immune cells from HIV/AIDS donors. The research demonstrated that the Geron compounds increased the proliferative capacity of cytotoxic T-cells and their ability to produce a virus-fighting molecule, gamma Interferon.

--Stem Cells published Geron studies which demonstrated that human embryonic stem cells (hESCs) can be propagated in culture using defined growth factors without the need for feeder cells or media conditioned by feeder cells. The results represented a major step forward in the development of scalable systems to culture hESCs for the production of therapeutic cell products.

Geron is a biopharmaceutical company developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding future financial results of Geron Corporation and potential applications of Geron's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, need for regulatory approvals or clearances, the maintenance of our intellectual property rights and need for future capital. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2004.

GERON CORPORATION
            CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                              (UNAUDITED)

                                                THREE MONTHS ENDED
                                                     MARCH 31,
(In thousands, except share and                  2005         2004
per share amounts)                           ------------ ------------

License fees and royalties                   $        59  $       248

Operating expenses:
  Research and development                         6,473        5,718
  Acquired in-process research technology             --       45,150
  General and administrative                       3,949        1,391
                                             ------------ ------------
 Total operating expenses                         10,422       52,259
                                             ------------ ------------
Loss from operations                             (10,363)     (52,011)

Interest and other income                            847          498
Interest and other expense                          (172)        (170)
                                             ------------ ------------
Net loss                                     $    (9,688) $   (51,683)
                                             ============ ============

Basic and diluted net loss per share         $     (0.18) $     (1.28)
                                             ============ ============
Weighted average shares used in calculation
   of basic and diluted net loss per share    54,175,184   40,449,815
                                             ============ ============



                 CONDENSED CONSOLIDATED BALANCE SHEETS

                                              MARCH 31,   DECEMBER 31,
(In thousands)                                  2005         2004
                                             ------------ ------------
                                             (Unaudited)    (Note 1)
Current assets:
  Cash, restricted cash and cash equivalents    $  8,060     $ 10,376
  Marketable securities                          116,955      110,118
  Interest and other receivables                   1,638        1,550
  Other current assets                             2,824        2,733
                                             ------------ ------------
Total current assets                             129,477      124,777

Property and equipment, net                        1,975        2,089
Deposits and other assets                          3,476        3,876
Intangible assets                                    942        1,131
                                             ------------ ------------
                                                $135,870     $131,873
                                             ============ ============

Current liabilities                                5,142        8,458
Noncurrent liabilities                               988        1,352
Stockholders' equity                             129,740      122,063
                                             ------------ ------------
                                                $135,870     $131,873
                                             ============ ============

Note 1: Derived from audited financial statements included in the
        Company's Annual Report on Form 10-K, filed with the SEC.